About 31 results found for searched term "CK2-IN-7" (0.108 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41417 | CK2-IN-7 | Casein Kinase |
| CK2-IN-7 is an inhibitor of casein kinase 2 (CK2). | ||
| M49539 | ROCK2-IN-7 | ROCK |
| ROCK2-IN-7 is a kinase inhibitor targeting to ROCK2. | ||
| M1817 | Y-27632 dihydrochloride | ROCK |
| Y27632; Y-27632 2HCl | ||
| Y-27632 is a potent, selective inhibitor of Rho-associated protein kinases (ROCK) with IC50 values of 140-220 nM for ROCK1 and ROCK2. In addition, Y-27632 inhibited LPA-induced entosis. | ||
| M3270 | Docosanol | Anti-infection |
| Behenyl alcohol | ||
| Docosanol is a saturated fatty alcoholused traditionally as an emollient, emulsifier, and thickener in cosmetics, nutritional supplement. (ED50=2.5 mg/ml for plaque inhibition, and ED50=1.7 mg/ml for inhibition of virus production) | ||
| M1545 | Infliximab | TNF Receptor |
| Remicade; Avakine; CT-P13 | ||
| Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that blocks TNF-α interaction with TNF-α receptor 1 (TNFR1) and TNFR2. For the treatment of autoimmune diseases. Infliximab is available in BALB/ C or C57/Bl6 mice. | ||
| M4079 | (R)Ginsenoside-Rh2 | MMP |
| 20(R)-Ginsenoside Rh2, a matrix metalloproteinase (MMP) inhibitor, acts as an anti-proliferative agent in cells. It has anticancer effects by blocking cell proliferation and causing G1 phase arrest. 20(R)-Ginsenoside Rh2 induces apoptosis and has anti-inflammatory and antioxidant activities. 20(R)-Ginsenoside Rh2 inhibited the replication and proliferation of mouse and human γ herpevirus 68 (MHV-68) with an IC50 of 2.77 μM against mouse MHV-68. | ||
| M5123 | Y-39983 dihydrochloride | ROCK |
| Y-33075 dihydrochloride | ||
| Y-39983 (Y-33075) dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM, derived from Y-27632, inhibited ROCK more potently than Y-27632. | ||
| M6876 | L-161982 | Prostaglandin Receptor |
| L161982 | ||
| L-161982 is a EP4 receptor antagonist that is selective over all other members of the prostanoid receptor family (Ki values are 0.024, 0.71, 1.90, 5.10, 5.63, 6.74, 19 and 23 μM for human EP4, TP, EP3, DP, FP, IP, EP1 and EP2 receptors respectively). L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. | ||
| M8837 | UK-78282 monohydrochloride | Potassium Channel |
| UK-78282 hydrochloride | ||
| UK-78282 is a novel, potent and selective Kv1.3 blocker with an IC50 of 200 nM. UK-78282 effectively suppresses human T-lymphocyte activation in vitro. UK-78282 binds to residues at the inner surface of the channel overlapping the site of action of verapamil. | ||
| M10654 | Ajmalicine (Raubasine) | Adrenergic Receptor |
| Raubasine | ||
| Ajmalicine (Raubasine) is an adrenolytic agent which preferentially blocks alpha 1-adrenoceptor than alpha 2-adrenoceptor. Ajmalicine (Raubasine) is an reversible non-competitive nicotine receptor antagonist with an IC50 of 72.3 μM. | ||
| M10782 | APG-1387 | IAP |
| APG-1387 is a divalent SMAC mimetic that is an IAP antagonist that blocks the activity of the IAP family of proteins (XIAP, cIAP-1, cIAP-2, and ML-IAP). APG-1387 induces degradation of cIAP-1 and XIAP proteins as well as caspase-3 activation and PARP lysis, leading to apoptosis. APG-1387 can be used for the study of hepatocellular carcinoma, ovarian cancer and nasopharyngeal carcinoma. | ||
| M13731 | ROCK inhibitor-2 | ROCK |
| ROCK inhibitor-2 is a selective dual ROCK1 and ROCK2 inhibitor with IC50s of 17 nM and 2 nM, respectively. | ||
| M20381 | WAY-302713-A | Casein Kinase |
| CK2α-IN-1 | ||
| WAY-302713-A is a selective, non-ATP-competitive CK2α inhibitor (IC50=7.0 µM; Ki=1.6 µM) for cancer-related studies. | ||
| M20753 | TBOPP | Others |
| TBOPP is a selective inhibitor of dedicator of cytokinesis (DOCK1, Dock180) that inhibits DOCK1-mediated Rac activation with IC50 of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with Kd of 7.1 μM. TBOPP exhibits anti-tumor activity. | ||
| M21033 | CK1-IN-1 | Casein Kinase |
| PUN51207, Compound 1C | ||
| CK1-IN-1 (PUN51207, Compound 1C) is an inhibitor of casein kinase 1 (CK1) with IC50 of 15 nM, 16 nM and 73 nM for CK1δ, CK1ε and p38α MAPK, respectively. | ||
| M28240 | AZD4320 | Bcl-2 |
| AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively. | ||
| M28960 | CPUY201112 | HSP |
| CPUY201112 is a potent heat shock protein Hsp90 inhibitor with Kd of 27 nM. CPUY201112 induces p53-mediated apoptosis in MCF-7 cells, resulting in cell cycle arrest, which can be used in cancer research. | ||
| M29455 | DDO-7263 | Keap1-Nrf2 |
| DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD). | ||
| M30043 | TPCK | Serine/Threonine Protease |
| L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK | ||
| TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is a potent serine protease inhibitor that reacts with the retinoblastoma protein (RB)-binding core of HPV-18 E7 protein and abolish its RB-binding capability. TPCK is able to modify E7 protein in live keratinocytes following its addition to the culture medium. | ||
| M30518 | ARP-100 | MMP |
| ARP-100 is a potent and selective matrix metalloproteinase MMP-2 inhibitor (IC50=12 nM). ARP-100 interacts with S1＇ pocket of MMP-2 and shows anti-invasive properties in an in vitro model of invasion on matrigel. ARP-100 shows the less inhibitory activity towards MMP-1 (>50 μM), MMP-3 (4.5 μM), MMP-7 (>50 μM), and MMP-9 (0.2 μM). | ||
| M30744 | TC-E 5001 | PARP |
| TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively. | ||
| M30952 | Lck inhibitor 2 | Src-bcr-Abl |
| Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively IC50 Value: 13 nM(Lck) [1] Target: Src family kinase Lck inhibitor 2(Compound 9) inhibited 48 kinases with %control < 1 (33 of them tyrosine kinases, almost half of the 71 tyrosine kinases in the panel). A further 27 kinases were bound with %control < 10. Kd values for 16 kinases were determined and found to be below 100 nM. These included TXK (10 nM). | ||
| M30963 | TTP-8307 | Anti-infection |
| TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC50=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP). | ||
| M31200 | CK7 | CDK |
| CK-7 | ||
| CK7 is a Cdk2/9 inhibitor, which can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367. | ||
| M41415 | CK1-IN-2 | Casein Kinase |
| CK1-IN-2 is a potent CK1 inhibitor with an IC50 values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively. | ||
| M41592 | THK01 | ROCK |
| THK01 is a potent ROCK2 inhibitor with IC50 values of 5.7 and 923 nM for ROCK2 and ROCK1, respectively. | ||
| M45287 | CK2/ERK8-IN-1 | Casein Kinase |
| CK2/ERK8-IN-1 is a dual inhibitor of casein kinase 2 (CK2) (Ki 0.25 µM) and ERK8 (MAPK15, ERK7), both with IC50s of 0.50 µM. In addition, CK2/ERK8-IN-1 binds to PIM1, HIPK2, and DYRK1A with Ki values of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. 15.25 µM and 11.9 µM, respectively, and also has pro-apoptotic activity. | ||
| M45292 | TBCA | Casein Kinase |
| TBCA is a highly selective inhibitor of casein kinase II CK2 with an IC50 of 110 nM and a Ki of 77 nM.In addition, TBCA exhibits selectivity for CK1, DYRK1A and 27 other kinases. | ||
| M45297 | CK2-IN-3 | Casein Kinase |
| CK2-IN-3 is a selective and potent CK2 inhibitor (Kd: 12 nM) with IC50 values of 1.51 μM (CK2α), 7.64 μM (CK2α') and can be used in cancer-related studies. | ||
| M45300 | CK2/PIM1-IN-1 | Casein Kinase |
| CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1 with IC50 values of 3.787 μM and 4.327 μM for the effects of CK2 and PIM1, respectively.CAS 번호410483-84-5 | ||
| M45305 | CK2-IN-9 | Casein Kinase |
| CK2-IN-9 is a potent selective inhibitor of CK2 kinase with an IC50 of 3 nM, and also reduces the reporter activity of Wnt with an IC50 of 75 nM. In addition, CK2-IN-9 is characterized by low exposure (AUC=0.36 μM/h) and high clearance (CL=65 mL/min/kg) in rats. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
